截至2025年7月22日，创新药ETF天弘(517380)近1周累计上涨3.93%。 资金流入方面，创新药ETF天弘(517380)近22个交易日合计"吸金"2367.04万元。 截至2025年7月23日 10:10，生物医药ETF(159859)上涨1.50%，成交4087.03万元。跟踪指数国证生物医药指数(399441)强势上涨1.69%，成分股昭衍新药 (603127)上涨8.76%，康龙化成(300759)上涨7.76%，凯莱英(002821)上涨6.66%，泰格医药(300347)，药明康德(603259)等个股跟涨。 截至2025年7月22日，生物医药ETF(159859)近1周累计上涨2.84%，涨幅排名可比基金第一。生物医药ETF(159859)近1周日均成交1.10亿元，居可比基金第 一。 截至2025年7月23日 10:08，创新药ETF天弘(517380)上涨1.89%，涨幅居行业ETF榜第一，盘中成交464.89万元。跟踪指数恒生沪深港创新药精选50指数 (HSSSHID)强势上涨2.13%，成分股康龙化成(03759)上涨11.51%，药明合联(02268)上涨10.73%，昭衍新 ...

国泰海通证券指出，A股方面，大幅增配创业板，略增科创板，减配主板。风格上，主动基金AH股持 仓结构有一定调整。一方面，从自下而上景气趋势出发，增配以中证500为代表的中盘成长股，如科技 硬件、医药与新消费等，而减配龙头权重个股，这使得基金个股配置集中度有明显回落。另一方面是明 显提升了大金融板块仓位，并对保险/城商行/股份行的大幅增配，主动顺应了公募基金改革的趋势。对 于传统领域的周期和消费股基金则以减配为主。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 截至7月22日，该ETF最新流通份额为36.26亿份，最新流通规模为86.92亿元。 创业板ETF天弘（159977）紧密跟踪创业板指数（399006.SZ），该指数是深交所多层次资本市场的核 心指数之一，由最具代表性的100家创业板上市企业股票组成，反映创业板市场层次的运行情况。创业 板指数新兴产业、高新技术企业占比高，成长性突出，兼具价值尺度与投资标的的功能。截至7月21 日，创业板指前十大指数中包含宁德时代、东方财富、汇川技术、中际旭创、迈瑞医疗等。创业板ETF 天弘（159977）同时配置场外创 ...

医疗板块突围进行时！7月23日早盘，CXO概念强势反弹，昭衍新药劲涨超8%，康龙化成涨超6%，凯 莱英、九洲药业、泰格医药、药明康德等均大幅跟涨。 A股最大医疗ETF（512170）盘中上探2%，盘中价再刷近4个月新高！场内交投活跃，开盘30分钟成交 额突破4亿元。 | 一度 | 证券代码 | 证券酒称 | 预告净利润下限 | 预告净利润上限 | 预告净利润同比增长下限 | 预告净利润同比增长上限 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 【报告剧 今年中报 | [提古期] 今年中报 | 【报告期 今年中版 | 【报告则】今年中报 | | | | | | [单位] 亿元 | [单位] 亿元 | [单位] 米 | [中位] %↓ | | | | 6031275H | 脂肪新药 | 0.5032 | 0.7549 | 129,6474 | | 144,4712 | | 2 | 688351 SH | 影曲 | 0.3000 | 0.3500 | 76,3400 | | 105,7300 | | 3 | 6032595H | 药明康德 ...

Core Viewpoint - A recent incident of violence in a laboratory of Kanglong Chemical has raised concerns about the company's internal culture and management, coinciding with a disappointing earnings forecast that highlights declining profitability despite revenue growth [3][4][5]. Financial Performance - Kanglong Chemical's revenue forecast for the first half of 2025 is projected to be between 6.3 billion and 6.5 billion yuan, representing a year-on-year growth of 13% to 16%. However, net profit is expected to decline by 36% to 39%, amounting to 679 million to 713 million yuan [3][4]. - The company's revenue for 2023 was 11.538 billion yuan, a growth of 12.39%, marking the lowest growth rate since 2015 and the first time in nine years that growth fell below 20% [4]. - The forecast for 2024 indicates a further slowdown, with revenue growth expected to drop to single digits at 6.39%, and a significant decline in net profit by 26.8% [4]. Business Segments - Kanglong Chemical's CGT and large molecule business has been identified as a drag on overall performance, with revenue for this segment in 2024 expected to be 408 million yuan, a decline of 4%, while costs surged by 33% to 612 million yuan, resulting in a record loss of 204 million yuan [6]. - The company has been facing challenges in the CGT sector due to a slowdown in global drug development demand and increased competition, leading to downward pressure on service prices [6][7]. Market Dynamics - Domestic revenue from Chinese clients is projected to decline by 6.46% to 1.847 billion yuan, while revenue from North American clients is expected to grow by 6.11% to 7.853 billion yuan, indicating a disparity in performance across regions [8]. - The company is advised to enhance early-stage development collaborations and explore new service models to improve client retention and pricing power [8]. Shareholder Activity - Significant shareholder sell-offs have raised concerns, with major shareholders having reduced their holdings by 77.95 million shares since 2022, equivalent to 4.835 billion yuan, which is nearly three times the company's projected net profit for 2024 [9][10]. - The accelerated pace of share reduction and the loosening of concentrated shareholding structures may weaken governance and control within the company, potentially impacting strategic decision-making [10].

CRO龙头康龙化成（300759）(300759.SZ)出圈了，原因竟是员工在办公室互殴。 近几日，网络上流传的视频显示，康龙化成的两名女员工在办公室大打出手，多名员工围观竟无人劝 阻。这一现象，引发市场对康龙化成公司文化的质疑。 康龙化成方面回应潇湘晨报称，这是员工排队之间的小矛盾，不影响公司经营。 康龙化成于2004年成立，2019年实现A股和H股上市，是一家全球领先的全流程一体化医药研发生产服 务平台。2021年，公司A股股价一度大涨26倍，市值逼近2000亿元。如今，公司市值约为468亿元，缩 水了1400多亿元。 与之对应的是，康龙化成的业绩增速放缓。根据最新发布的业绩预告，2025年上半年，公司预计实现归 母净利润约6.79亿元—7.13亿元，同比增长36%—39%，但经调整的非《国际财务报告准则》下归母净 利润同比增长仅为6%—11%。 康龙化成的股东频频减持。据不完全统计，公司股东通过减持累计套现超200亿元，其中，实际控制人 及一致行动人累计套现30亿元左右。 称员工打架同事围观为小事 康龙化成出圈，却源于员工在办公室互殴，引发了市场质疑。 近日有多位网友发帖，称在康龙化成北京一园区有两个女 ...

Core Viewpoint - The article highlights a significant surge in the innovative drug sector, driven by new policies from the National Healthcare Security Administration aimed at supporting the development of innovative drugs and optimizing procurement processes [1][2]. Summary by Sections Innovative Drug Market Surge - On July 17, there was a notable increase in the stock prices of innovative drug companies, with companies like ShenZhou Cell rising over 15% and KangnuoYa increasing over 14% [1]. - The article mentions that the 11th batch of national drug centralized procurement has been initiated, emphasizing that new drugs will not be included in centralized procurement to protect industry innovation [1]. Policy Support for Innovative Drugs - The "Measures" issued on June 30 by the National Healthcare Security Administration and the National Health Commission aim to support the entire chain of innovative drug development from laboratory to bedside [1]. - The measures include dynamic adjustments to the medical insurance catalog, allowing eligible innovative drugs to be included, and establishing more scientifically reasonable payment standards [1]. Establishment of Commercial Health Insurance Directory - A groundbreaking proposal to establish a "Commercial Health Insurance Innovative Drug Directory" is introduced, which will include innovative drugs with significant clinical value that exceed basic medical insurance coverage [2]. - Drugs in this directory will enjoy special treatment, such as confidential price negotiations and exemption from centralized procurement monitoring, creating new payment channels for high-priced breakthrough therapies [2]. Investment Opportunities - Analysts from Bohai Securities suggest that the introduction of innovative drug policies and the potential establishment of the commercial health insurance directory present investment opportunities in related innovative drug companies and their supply chains [2]. - Xiangcai Securities predicts that by 2025, the domestic innovative drug industry may experience a turning point, shifting from capital-driven to profit-driven trends, leading to dual recovery in performance and valuation [2].

Core Viewpoint - The article discusses the recent performance and challenges faced by Kanglong Chemical (康龙化成), highlighting a recent incident among employees and the company's financial forecasts for 2025, indicating a mixed outlook with revenue growth but declining net profits [3][6]. Financial Performance - Kanglong Chemical expects total revenue for the first half of 2025 to be between 6.3 billion to 6.5 billion, representing a year-on-year growth of 13% to 16%. However, net profit is projected to decline by 36% to 39%, primarily due to a significant one-time gain from equity disposal in the previous year [6]. - The company reported a total revenue of 12.28 billion in 2024, with a growth rate of 6.39% compared to 2023. The revenue breakdown shows that laboratory services accounted for 57.40% of total revenue, while CMC services contributed 24.35% [8][12]. Industry Context - Kanglong Chemical is a prominent Contract Research Organization (CRO) in China, assisting clients in accelerating drug innovation through various services, including laboratory services and clinical research [7]. - The CRO sector was previously highly sought after in the capital market, with Kanglong Chemical's stock price increasing over 26 times within three years post-IPO, reaching a market capitalization close to 200 billion [9]. - The company has faced challenges since the US-China trade tensions, leading to a significant slowdown in growth, with 2024 revenue growth dropping to single digits [12]. Operational Strategy - To mitigate market challenges, Kanglong Chemical has established 21 R&D centers and production bases across China, the UK, and the US, with North America being the primary revenue source, contributing over 60% [17]. - The company reported a 16% year-on-year revenue growth in Q1 2025, indicating a positive trend despite previous high growth rates [22]. Shareholder Activity - Since its IPO, major shareholders, including the controlling shareholder and executives, have continuously reduced their holdings, with total cashing out amounting to 21.45 billion in the A-share market [25][26].

Group 1 - The A-share CRO (Contract Research Organization) sector experienced a significant rally in the afternoon, with notable stocks such as Chengdu Xian Dao hitting the daily limit up [1] - MediXy and Hite Bio both surged over 14%, indicating strong investor interest and market momentum [1] - Other companies in the sector, including Zhaoyan New Drug, Yinuosi, Sunshine Nuohe, Kanglong Huacheng, and Puris, also saw positive gains, reflecting a broader trend in the CRO market [1]

Group 1: Company Performance Forecasts - Zhongshe Co., Ltd. expects a net loss of 6 to 8 million yuan for the first half of 2025, compared to a profit of 18.83 million yuan in the same period last year [1] - Jiangfeng Electronics anticipates a net profit of 247 to 267 million yuan for the first half of 2025, representing a growth of 53.29% to 65.70% year-on-year [1] - Naipu Mining forecasts a net profit of 15 to 22.5 million yuan for the first half of 2025, a decline of 73.32% to 82.21% compared to the previous year [7] - Runjian Co., Ltd. expects a net profit of 35 to 52.5 million yuan for the first half of 2025, a decrease of 78% to 85% year-on-year [13] - Kanglong Chemical predicts a net profit of 679 to 713 million yuan for the first half of 2025, down 36% to 39% from the previous year [14] Group 2: Shareholder Actions - Tianyuan Co., Ltd. plans to reduce its shareholding by up to 0.76% through a concentrated bidding process [2] - Sanwei Tiandi intends to reduce its shareholding by up to 4.07% through concentrated bidding or block trading [3] - Zhongfu Shenying plans to reduce its shareholding by up to 1% due to personal funding needs [4] - Hengfeng Information intends to reduce its shareholding by up to 3% through concentrated bidding or block trading [6] - *ST Yanzhen's stock will be suspended for inspection due to abnormal trading fluctuations [9] Group 3: Corporate Transactions - *ST Weir plans to acquire 51% of Shanghai Zijiang New Materials Technology Co., Ltd. for 546 million yuan [10] - Greenland plans to introduce overseas strategic investors for its subsidiary QINGMEI to enhance global competitiveness [12] - Taihe Co., Ltd. intends to acquire the remaining 51% stake in Guangdong Haode Crop Technology Co., Ltd. for 22.083 million yuan [13] - Weichai Heavy Machinery is planning to acquire 100% of Changzhou Fiberglass Shipyard Co., Ltd. [15] - Guolian Aquatic plans to introduce a new shareholder through capital increase for its subsidiary [16]

点评：HSK47388作为一款自主研发的高选择性口服药物，在临床前研究中展现出显著的剂量依赖性抗 炎效果和良好安全性，凸显其在自身免疫疾病领域的治疗潜力。其较大的安全窗为后续临床研究提供了 有利基础，若转化成功，有望填补现有疗法空白。 NO.2 康龙化成上半年净利同比预降36%至39% 每经记者｜陈星 每经编辑｜杨夏 ｜ 2025年7月16日 星期三 ｜ NO.1 海思科医药创新药HSK47388片获得FDA同意开展临床试验 HSK47388片是公司自主研发的口服、强效、高选择性的药物，拟用于自身免疫疾病的治疗。临床前研 究结果显示，HSK47388可以剂量依赖地抑制大鼠炎症反应，同时也表现出了良好的耐受性和较大的安 全窗，是一款极具开发潜力的药物，有望为自身免疫疾病患者提供一种新的治疗选择。 NO.5 百诚医药上半年净利同比预降逾九成 7月15日晚间，百诚医药发布2025年半年度业绩预告显示，公司上半年实现的归属净利润预计为0万元至 600万元，比上年同期下降95.53%至100%。百诚医药表示，2025年二季度公司加大自主研发技术成果转 化，收入环比增加。同时公司严格管控成本和费用，2025年上半年较20 ...